These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

829 related items for PubMed ID: 12885747

  • 1. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations.
    Circulation; 2003 Aug 12; 108(6):684-90. PubMed ID: 12885747
    [Abstract] [Full Text] [Related]

  • 2. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM.
    J Electrocardiol; 2009 Aug 12; 42(6):584-8. PubMed ID: 19631946
    [Abstract] [Full Text] [Related]

  • 3. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    Circulation; 2006 Mar 28; 113(12):1588-96. PubMed ID: 16534012
    [Abstract] [Full Text] [Related]

  • 4. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB.
    Circ Arrhythm Electrophysiol; 2008 Dec 28; 1(5):337-43. PubMed ID: 19808428
    [Abstract] [Full Text] [Related]

  • 5. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
    Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K.
    J Hum Hypertens; 2011 Mar 28; 25(3):178-85. PubMed ID: 20505749
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB, LIFE Study Investigators.
    Circulation; 2009 Apr 14; 119(14):1883-91. PubMed ID: 19332468
    [Abstract] [Full Text] [Related]

  • 7. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN, Devereux RB, Okin PM.
    J Electrocardiol; 2014 Apr 14; 47(5):630-5. PubMed ID: 25052475
    [Abstract] [Full Text] [Related]

  • 8. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    JAMA; 2004 Nov 17; 292(19):2343-9. PubMed ID: 15547161
    [Abstract] [Full Text] [Related]

  • 9. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlöf B, Devereux RB, Kjeldsen SE, Oikarinen L, Okin PM, LIFE Study Investigators.
    J Hypertens; 2006 Apr 17; 24(4):775-81. PubMed ID: 16531808
    [Abstract] [Full Text] [Related]

  • 10. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
    Okin PM, Hille DA, Kjeldsen SE, Lindholm LH, Edelman JM, Dahlöf B, Devereux RB.
    Am J Hypertens; 2010 Jul 17; 23(7):786-93. PubMed ID: 20395941
    [Abstract] [Full Text] [Related]

  • 11. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K.
    Circulation; 2007 Aug 14; 116(7):700-5. PubMed ID: 17664372
    [Abstract] [Full Text] [Related]

  • 12. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B.
    Hypertension; 2000 Nov 14; 36(5):766-73. PubMed ID: 11082141
    [Abstract] [Full Text] [Related]

  • 13. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Ruwald AC, Westergaard B, Sehestedt T, Kjeldsen SE, Lindholm LH, Wachtell K, Devereux RB, Ibsen H, Nieminen MS, Dahlöf B, Olsen MH.
    J Hypertens; 2012 Jun 14; 30(6):1252-9. PubMed ID: 22499288
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB.
    J Am Coll Cardiol; 2005 Mar 01; 45(5):705-11. PubMed ID: 15734614
    [Abstract] [Full Text] [Related]

  • 15. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H, Pedersen OL, Dahlöf B, Kjeldsen SE, Lindholm LH.
    Ugeskr Laeger; 2003 Jan 27; 165(5):456-9. PubMed ID: 12599843
    [Abstract] [Full Text] [Related]

  • 16. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB, de Faire U, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Hille DA, Dahlöf B.
    Curr Med Res Opin; 2007 Feb 27; 23(2):259-70. PubMed ID: 17288679
    [Abstract] [Full Text] [Related]

  • 17. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
    Palmieri V, Okin PM, de Simone G, Bella JN, Wachtell K, Gerdts E, Boman K, Nieminen MS, Dahlöf B, Devereux RB.
    J Hypertens; 2007 May 27; 25(5):1079-85. PubMed ID: 17414673
    [Abstract] [Full Text] [Related]

  • 18. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
    Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, Edelman JM, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahlöf B, LIFE Study Group.
    J Am Coll Cardiol; 2005 Sep 06; 46(5):770-5. PubMed ID: 16139123
    [Abstract] [Full Text] [Related]

  • 19. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
    Okin PM, Devereux RB, Liu JE, Oikarinen L, Jern S, Kjeldsen SE, Julius S, Wachtell K, Nieminen MS, Dahlöf B.
    J Hum Hypertens; 2004 Jun 06; 18(6):403-9. PubMed ID: 15057252
    [Abstract] [Full Text] [Related]

  • 20. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
    Søraas CL, Wachtell K, Okin PM, Dahlöf B, Devereux RB, Tønnessen T, Kjeldsen SE, Olsen MH.
    Blood Press; 2010 Jun 06; 19(3):145-51. PubMed ID: 20429689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.